RxDoctor Payments Data

Charles Nyhus, MD

Family Medicine · Harvey, NDNPI 1700954633

Payments from drug & device makers

$366in general payments, 2019–2025

Across 25 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$190
  • AbbVie$75
  • Merck$30
  • Vanda Pharmaceuticals Inc.$19
  • Lilly USA, LLC$18
  • E.r. Squibb & Sons, L.L.C.$13
  • plus $22 from 2 others

What the payments were for

  • Food & beverage$366100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$366 in reported general payments places this provider in the 65th percentile of 337 family medicine providers in North Dakota.

See all family medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$180,414
Medicare patients
428
Services billed
4,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban83$58,241
JardianceEmpagliflozin55$43,894
FarxigaDapagliflozin Propanediol29$23,686
RexultiBrexpiprazole27$19,551
JanuviaSitagliptin Phosphate33$19,525
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog71$18,874
OzempicSemaglutide15$15,115
ArexvyRsvpref3 Antigen/As01e/Pf41$12,977
Breo ElliptaFluticasone/Vilanterol31$12,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$12,418
ShingrixVaricella-Zoster Ge/As01b/Pf51$11,302
Janumet XrSitagliptin Phos/Metformin Hcl13$7,854
Spiriva RespimatTiotropium Bromide12$7,168
SymbicortBudesonide/Formoterol Fumarate22$5,886
MyrbetriqMirabegron12$5,847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Breo Ellipta, Trelegy Ellipta, Shingrix$11$49,514136 claims
MerckJanuvia, Janumet Xr$30$27,37946 claims
AbbVieLumigan, Synthroid$75$7,06342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 337 family medicine providers in North Dakota.

Other family medicine in Harvey

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →